Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Operating Leases (2022 - 2026)

TriSalus Life Sciences has reported Operating Leases over the past 5 years, most recently at $1.2 million for Q1 2026.

  • For Q1 2026, Operating Leases fell 8.39% year-over-year to $1.2 million; the TTM value through Mar 2026 reached $1.2 million, down 8.39%, while the annual FY2025 figure was $1.2 million, 7.6% down from the prior year.
  • Operating Leases for Q1 2026 was $1.2 million at TriSalus Life Sciences, down from $1.2 million in the prior quarter.
  • Over five years, Operating Leases peaked at $1.6 million in Q4 2022 and troughed at $1.2 million in Q2 2024.
  • A 5-year average of $1.3 million and a median of $1.3 million in 2023 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: dropped 21.91% in 2023 and later increased 14.26% in 2024.
  • Year by year, Operating Leases stood at $1.6 million in 2022, then decreased by 21.91% to $1.2 million in 2023, then rose by 6.83% to $1.3 million in 2024, then dropped by 7.6% to $1.2 million in 2025, then fell by 3.09% to $1.2 million in 2026.
  • Business Quant data shows Operating Leases for TLSI at $1.2 million in Q1 2026, $1.2 million in Q4 2025, and $1.2 million in Q3 2025.